Exosomal MicroRNA-320a Derived From Mesenchymal Stem Cells Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Activation by Suppressing CXCL9 Expression
Overview
Affiliations
Rheumatoid arthritis (RA), a chronic systemic inflammatory disease, is a primary cause of disability worldwide. The involvement of fibroblast-like synoviocytes (FLSs) in the regulation of the pathogenesis of RA has been highlighted. Mesenchymal stem cells (MSCs) are important candidates for cell-based treatment in many inflammatory autoimmune diseases. Herein, we identify whether MSC-derived exosomes loaded with microRNA-320a (miR-320a) regulate RA-FLSs. Synovial tissues from 22 patients with RA and 9 patients with osteoarthritis were collected. RA-FLSs were obtained from patients with RA, and their functions were evaluated by determining levels of interleukin-1β (IL-1β), IL-6, and IL-8 and by transwell migration and invasion assays. Dual luciferase reporter gene assays were employed to identify interaction between miR-320a and CXC chemokine ligand 9 (CXCL9). A co-culture system of MSC-derived exosomes and RA-FLSs were performed. The collagen-induced arthritis (CIA) mouse models with arthritis and bone damage were developed. Our results revealed the existence of reciprocal expression of miR-320a and CXCL9 in the synovial tissues obtained from patients with RA. CXCL9 knockdown or miR-320a upregulation suppressed the activation, migration, and invasion of RA-FLSs. CXCL9 was confirmed to be a target of miR-320a, and CXCL9 overexpression restored RA-FLS function in the presence of miR-320a. MSC-derived exosomes containing miR-320a mimic significantly suppressed RA-FLS activation, migration, and invasion and attenuated arthritis and bone damage in mice with CIA . Our study uncovers that MSC-derived exosomes participate in the intercellular transfer of miR-320a and subsequently inhibit the progression of RA. These results provide a novel potential therapeutic approach for RA treatment by increasing miR-320a in exosomes.
Aghajani S, Maboudi S, Seyhoun I, Nia R, Shabestari A, Sharif S Mol Biol Rep. 2025; 52(1):229.
PMID: 39948229 DOI: 10.1007/s11033-025-10290-z.
Du Z, Chu W, Peng X, Wu L, Liu Y, Yu G ACS Appl Mater Interfaces. 2025; 17(4):5752-5761.
PMID: 39803988 PMC: 11788986. DOI: 10.1021/acsami.4c16595.
Wu X, Li H, Meng F, Lui T, Pan X J Orthop Surg Res. 2024; 19(1):849.
PMID: 39702169 PMC: 11658229. DOI: 10.1186/s13018-024-05336-0.
Yang Z, Hou N, Cheng W, Lu X, Wang M, Bai S Cell Death Dis. 2024; 15(12):910.
PMID: 39695085 PMC: 11655635. DOI: 10.1038/s41419-024-07193-5.
Abebaw D, Akelew Y, Adugna A, Teffera Z, Tegegne B, Fenta A Front Immunol. 2024; 15:1499929.
PMID: 39624102 PMC: 11609219. DOI: 10.3389/fimmu.2024.1499929.